Probiotic-based Antiviral Systems and Therapies 2.0
Legal Citation
Summary of the Inventive Concept
A next-generation platform for predicting, preventing, and treating viral infections in mammals, leveraging advanced genomics, machine learning, CRISPR-Cas9 gene editing, and microfluidics to create personalized, targeted, and adaptive antiviral solutions.
Background and Problem Solved
The original patent disclosed the use of probiotic bacterial molecules for reducing the incidence and treatment of Rotavirus infections. However, this approach has limitations, such as the need for empirical identification of effective probiotic strains and the potential for variable efficacy. The new inventive concept addresses these limitations by integrating cutting-edge technologies to create a more proactive, precise, and effective antiviral system.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for predicting and preventing viral outbreaks, a method for creating personalized antiviral therapies, a composition combining live probiotic bacteria and synthetic antiviral molecules, a device for in-situ detection and elimination of viral pathogens, and a method for engineering probiotic bacteria to produce targeted antiviral molecules. These components work together to provide a comprehensive, adaptive, and effective solution for combating viral infections.
Novelty and Inventive Step
The new claims introduce several innovative elements, including the use of machine learning for identifying novel antiviral molecules, CRISPR-Cas9 gene editing for modifying probiotic bacteria, and microfluidics for in-situ detection and elimination of viral pathogens. These advancements significantly expand the capabilities and potential impact of the original patent, rendering the new inventive concept novel and non-obvious.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, gene editing tools, or microfluidic designs. Variations could involve applying the platform to different viral strains, incorporating additional diagnostic or therapeutic components, or integrating with existing healthcare systems.
Potential Commercial Applications and Market
The new inventive concept has significant commercial potential in the pharmaceutical, biotechnology, and healthcare industries. It could lead to the development of new antiviral therapies, diagnostic tools, and preventative measures, addressing a substantial unmet need in the market and improving public health outcomes.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Microbiology, virology, and probiotic therapeutic interventions, with expertise in bacterial molecular engineering, genomics, and antiviral therapeutic development
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in microbiology or biotechnology, familiar with probiotic bacterial manipulation, viral pathogen interactions, and molecular biology techniques including CRISPR gene editing and machine learning applications in biological systems
Obviousness Rationale
A person of ordinary skill would recognize that the PTD represents a predictable extension of the source patent's foundational probiotic antiviral approach, applying known biotechnological techniques to enhance the original therapeutic concept. The variations demonstrate standard scientific progression by integrating emerging technologies like machine learning and gene editing into the existing probiotic antiviral framework. These modifications represent incremental improvements using well-established molecular biology and computational techniques that would be obvious to a skilled practitioner in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,581 |
|---|---|
| Title | Antiviral methods and compositions comprising probiotic bacterial molecules |
| Assignee(s) | MICROSINTESIS INC. |